2017-18 Buprenorphine County prescriber counts and mean monthly census and buprenorphine treatment episode duration for Louisiana

Parish	State	Buprenorphine Patient Months- All Prescribers	Buprenorphine Episode- Primary Prescribers	Buprenorphine Episode Primary Prescriber Mean Patient Census	Buprenorphine Episode Mean Days' Supply
Ascension	LA	2,030	<10	56	249
Avoyelles	LA	2,131	<10	56	621
Bossier	LA	6,828	<10	76	426
Caddo	LA	38,763	38	90	290
Calcasieu	LA	16,305	28	56	294
Claiborne	LA	12	<10	1	30
Concordia	LA	745	<10	35	121
East Baton Rouge	LA	30,198	59	49	263
East Feliciana	LA	4,087	<10	359	366
Evangeline	LA	21	<10	3	197
Franklin	LA	118	<10	6	1,675
Iberia	LA	3,770	<10	70	353
Iberville	LA	343	<10	44	167
Jackson	LA	<10	<10	8	723
Jefferson	LA	67,642	84	74	290
Jefferson Davis	LA	528	<10	17	585
Lafayette	LA	29,433	47	54	360
Lafourche	LA	3,662	<10	48	492
La Salle	LA	71	<10	15	60
Lincoln	LA	3,104	<10	67	256
Livingston	LA	130	<10	8	50
Madison	LA	467	<10	22	1,110
Morehouse	LA	1,141	<10	80	797
Natchitoches	LA	2,347	<10	103	210
Orleans	LA	30,337	64	53	255
Ouachita	LA	5,206	<10	84	313
Plaquemines	LA	2,958	<10	74	585
Rapides	LA	7,695	17	47	419
Richland	LA	714	<10	27	217
Sabine	LA	431	<10	40	449
St. Bernard	LA	2,992	<10	58	333
St. Charles	LA	973	<10	28	947
St. James	LA	1,636	<10	135	511
St. John The Baptist	LA	243	<10	18	642
St. Landry	LA	4,282	<10	45	569
St. Martin	LA	783	<10	35	846
St. Mary	LA	<10	<10	1	42
St. Tammany	LA	42,695	38	94	336
Tangipahoa	LA	12,255	13	89	253
Terrebonne	LA	636	<10	16	64

Vermilion	LA	1,319	<10	48	300
Vernon	LA	31	<10	2	424
Washington	LA	1,114	<10	91	35
Webster	LA	139	<10	23	88
West Carroll	LA	4,270	<10	491	212
West Feliciana	LA	<10	<10	1	1,456
Winn	LA	652	<10	60	374

Table notes:

Table data was generated from IQVIA Longitudinal Prescription Data which captures approximately 90% of all prescriptions filled at retail pharmacies in the U.S. IQVIA web site accessible at: https://www.iqvia.com/solutions/realworld-evidence/real-world-data-and-insights.

Patient months: For every active buprenorphine prescriber, we calculated the total patient-months of care for 2017-2018. An active buprenorphine patient for one month contributed one patient-month of care. A patient possessing buprenorphine from a prescription in a month was considered an active patient; for example, a patient filling a 30-day prescription on September 15th was defined as an active patient in both September and October.

Episode and episode days' supply definition: Episodes that were active in 2017 and 2018 started with the first observed fill date of any buprenorphine prescription following a clean period, defined as at least a 90-day period after the day's supply of any prior buprenorphine prescription had run out. An episode lasted through the last day of the supply of medication for the last filled buprenorphine prescription, with no more than a 30-day gap between the last day's supply of one prescription and the filling of the subsequent prescription. Episode days' supply is the cumulative days' supply from the first filled prescription to the last day of supply of the last filled prescription. Overlapping buprenorphine prescriptions filled on the same day were treated as being taken concurrently; overlapping buprenorphine prescriptions not filled on the same day were treated as early refills and were treated as being take sequentially.

Episode primary prescriber: Episodes active in 2017 and 2018 as defined above in which the patient filled buprenorphine prescriptions from 2 or more prescribers were attributed to the prescriber (the primary prescriber) who wrote the majority of buprenorphine days of supply during the episode. Note that not all active prescribers were primary prescribers for an episode; examples include a prescriber who may have written one prescription during an episode to cover for the primary prescriber or a prescriber who started the episode but then transfrerred care of the patient to a primary prescriber who was responsible for more of the days supply than the initial prescriber.

Primary prescriber patient census: For each prescriber, the number of patients with an active episode in 2017 or 2018 for which the prescriber was the primary prescriber.